Education
About Us
Working with TipRanks
Follow Us
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
VYNE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.57 - $4.30
Previous CloseN/A
Volume117.27K
Average Volume (3M)76.09K
Market Cap
$28.59M
Enterprise Value$9.95M
Total Cash (Recent Filing)$49.51M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.84
Next Earnings
May 08, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding15,209,862
10 Day Avg. Volume56,259
30 Day Avg. Volume76,086
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)61.09
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit19.87
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
$6.19Price Target Upside229.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
VYNE Therapeutics News
See All VYNE News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase IIb study evaluating repibresib gel has demonstrated rapid and meaningful clinical benefit, as well as a favorable safety profile with limited systemic exposure in earlier trials.
Financial StabilityVYNE ended FY24 with $61.5M in cash and equivalents which the company is guiding as sufficient to fund operations into 2H26.
Bears Say
Market CompetitionPsoriasis is a relatively mature market and looks like a well-suited steppingstone for VYN202 to demonstrate clinical PoC.
---
Ownership Overview
11.35% Insiders
5.57% Mutual Funds
31.85% Other Institutional Investors
47.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VYNE FAQ
What was VYNE Therapeutics’s price range in the past 12 months?
VYNE Therapeutics lowest stock price was $1.57 and its highest was $4.30 in the past 12 months.
What is VYNE Therapeutics’s market cap?
VYNE Therapeutics’s market cap is $28.59M.
When is VYNE Therapeutics’s upcoming earnings report date?
VYNE Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 57 days.
How were VYNE Therapeutics’s earnings last quarter?
VYNE Therapeutics released its earnings results on Mar 06, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.303 by $0.023.
Is VYNE Therapeutics overvalued?
According to Wall Street analysts VYNE Therapeutics’s price is currently Undervalued.
Does VYNE Therapeutics pay dividends?
VYNE Therapeutics does not currently pay dividends.
What is VYNE Therapeutics’s EPS estimate?
VYNE Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does VYNE Therapeutics have?
VYNE Therapeutics has 15,209,862 shares outstanding.
What happened to VYNE Therapeutics’s price movement after its last earnings report?
VYNE Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.303. Following the earnings report the stock price went down -2.51%.
Which hedge fund is a major shareholder of VYNE Therapeutics?
Currently, no hedge funds are holding shares in VYNE
---
VYNE Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.19 (229.26% Upside)
$6.19 (229.26% Upside)
Insider Transactions
Bought Shares
Worth $43.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.14%
12-Months-Change
Fundamentals
Return on Equity
-56.54%
Trailing 12-Months
Asset Growth
-31.51%
Trailing 12-Months
Company Description
VYNE Therapeutics
Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded in October, 2011 and is headquartered in Redwood City, CA.
---
VYNE Stock 12 Month Forecast
Average Price Target
$6.19
▲(229.26% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Cidara Therapeutics
―
Blueprint Medicines
―
Aclaris Therapeutics
―
Journey Medical Corp
―
Best Analysts Covering VYNE
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-13.83%
reiterated a buy rating 7 days ago
Copying Rami Katkhuda's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -13.83% per trade.
---